Transforming growth factor beta family member (TGF-β family member)

The **transforming growth factor beta (TGF‑β) superfamily** comprises over 30 structurally related cytokines that regulate fundamental biological processes including cell proliferation, differentiation, apoptosis, migration and immune responses across nearly all tissues. Members are grouped into several major subfamilies such as the canonical transforming growth factors beta (TGF‑β1/2/3), bone morphogenetic proteins (BMPs), activins/inhibins and others. These ligands signal through heteromeric complexes of serine/threonine kinase receptors at the cell surface—type II receptors recruit type I partners upon ligand binding—which then activate intracellular SMAD transcription factors to modulate gene expression programs relevant to development and adult tissue homeostasis. Dysregulation contributes to diverse pathologies including cancer progression/metastasis/fibrosis/cardiovascular diseases/developmental syndromes[1][6][7]. Because “transforming growth factor beta family member” does not refer to a unique entity but rather an entire class/family with varied functions/mechanisms/disease roles/drug interactions/safety profiles depending on the precise protein involved—it should not be used as a canonical therapeutic target name.

Other names

TGF-beta superfamilyTGF-β familyTransforming growth factor-beta-related proteinBone morphogenetic proteins (BMPs) [as subfamily]Growth differentiation factors (GDFs) [as subfamily]Activins and inhibins [as subfamilies]

Varies by drug and target; generally includes inhibition of ligand-receptor binding, blockade of receptor kinase activity, neutralization by antibodies/traps, or interference with downstream SMAD signaling